Year: 2023
Type: article
Abstract: PURPOSE OF REVIEW: -agonist (SABA) use. This comprised an online survey (Phase 1), forum discussion and statement development (Phase 2), and statement adjudication (Phase 3). RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with ≥4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts (n = 8) reached consensus (median Likert score, interquartile range) that use of ≥3 SABA canisters/year is associated with increased risk of exacerbation and asthma-related death (5, 4.75-5); SABA use history should be solicited at every patient visit (5, 4.75-5); usage patterns over time, not absolute thresholds, should guide response to SABA overuse (5, 4.5-5). Future asthma guidelines should include clear recommendations regarding SABA usage, using expert-led thresholds for action.
Institutions: University of Michigan, Michigan Medicine, Columbia University, Dignity Health, California Allergy and Asthma Medical Group, Children's Mercy Hospital, University of Missouri–Kansas City, Pulmonary and Allergy Associates, Rutgers New Jersey Medical School, University of Kansas Medical Center
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,990
Funder: Teva Pharmaceutical Industries
OpenAlex ID: W4388912330